Long-term Outcomes in Patients With Primary Aldosteronism After Treatment
试验速览
- 阶段
- 不适用
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- change in systolic blood pressure before and after treatment
研究概览
简要总结
Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. PA is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands).
It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA.
The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 14 Years 至 100 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with suspected primary aldosteronism
排除标准
- 未提供
结局指标
主要结局
change in systolic blood pressure before and after treatment
时间窗: six months after treatment
change in systolic blood pressure
次要结局
- change in systolic blood pressure before and after treatment(through study completion, an average of 5 years)
- Renal Progression(through study completion, an average of 5 years)
- cardiovascular outcome(through study completion, an average of 5 years)
- chronic kidney disease(through study completion, an average of 5 years)
- variables that predict unilateral disease(through study completion, an average of 5 years)
- change in diastolic blood pressure before and after treatment(through study completion, an average of 5 years)
- variables that predict blood pressure response(through study completion, an average of 5 years)